Patent classifications
C07C235/40
EP4 agonists as therapeutic compounds
Described herein are compounds that are EP.sub.4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP.sub.4 receptors.
EP4 agonists as therapeutic compounds
Described herein are compounds that are EP.sub.4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP.sub.4 receptors.
COMPOUND FOR CAPPING LAYER AND ORGANIC LIGHT EMITTING DEVICE INCLUDING SAME
A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.
COMPOUND FOR CAPPING LAYER AND ORGANIC LIGHT EMITTING DEVICE INCLUDING SAME
A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.
1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS
A compound of formula (I)
##STR00001##
wherein R, R.sup.1, R.sup.2, R.sup.3, Y, Y.sup.1, a, X, and Z are as defined herein.
The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS
A compound of formula (I)
##STR00001##
wherein R, R.sup.1, R.sup.2, R.sup.3, Y, Y.sup.1, a, X, and Z are as defined herein.
The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure:
##STR00001##
ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure:
##STR00001##
Indene derivatives and uses thereof
The present invention relates to compounds of formula (I): ##STR00001## including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.
Indene derivatives and uses thereof
The present invention relates to compounds of formula (I): ##STR00001## including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.